Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Junkyardawg who wrote (38632)	5/11/1999 3:08:00 PM
From: HandsOn	Read Replies (2) \| Respond to of 90042

Bids might be a short term play here, over 5 mln volume.

To: Junkyardawg who wrote (38632)	5/11/1999 3:20:00 PM
From: Jon Stept	Respond to of 90042

How about AMGEN... I think they are the most well known blue-chip of the sector because they have multiple products in the pipeline, so if one fails or succeeds the stock price volatilty is reduced. There was a pretty cool article I read about 2 years ago about how the biotech companies are looking to attack the maturing baby-boomer market with a slew of drugs that will affect hormone levels to make people look and feel younger (ya know... keep things up and running... ahem....) lots and lots of products that have nothing to do with illness and would be relatively easy for these companies to come up with. Not to mention the all the living tissue varieties that they will be generating in a freaking petri dish. Ya know, a hamiken, or how about some purger or hork? Vegetarians are gonna have an ethical spastic fit over this stuff. JMO Jon :)